T2B Press Pass to JPM

Oliver Barnes is the FT’s US pharmaceutical and biotech correspondent based in New York, writing about scientific innovation, blockbuster drugs and access to healthcare in the world’s biggest economy. Oliver previously covered gambling, tobacco and hospitality companies as the FT’s leisure industries correspondent. He was nominated for a British Journalism Award for travel article of the year alongside colleagues for a features piece on extreme tourism.

His first role at the FT was covering health policy and science for the FT. He was awarded a journalism prize by the Royal Statistical Society for his coverage of the pandemic. Before joining the FT, Oliver worked for BBC News, writing articles for Reality Check, a BBC fact-checking service, and reporting for TV and radio outlets including the News at Six, Radio 4 and the World Service.

Brad Loncar is the founder of BiotechTV, which offers news and features from across the biotech industry. Prior to this, he was a biotechnology industry investor and CEO of Loncar Investments and the creator of two Nasdaq-listed biotech focused exchange-traded funds. Brad previously worked in the financial services industry at Franklin Templeton Investments where he was a member of the Management Training Program, and was appointed to serve in a Senior Advisor role at the U.S. Department of the Treasury.

Gabrielle Masson is a senior editor for Fierce Biotech, where she engages in live and virtual events, frequently speaks on the Top Line Podcast, and has presented on the floor of the New York Stock Exchange.

Prior to Fierce, Gabrielle worked at Becker’s Hospital Review, where she reported on public health and the pandemic. She has a background in data analysis and criminal justice, and graduated with a degree in creative writing after studying at the University of Wisconsin-Madison and the University of Cape Town.

​Gabrielle is the recipient of a regional award for her headline writing and her creative writing has been featured in numerous publications.